New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life

Follow-up data show substantial reductions in phlebotomy use persisting after final dose

Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026

Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2026 Annual Congress.

Divesiran data presented at EHA show improvements in PV-related symptoms and quality-of-life, complementing the substantial reductions in phlebotomy use as previously reported. Additional analyses also showed substantial reductions in phlebotomy use persisted well beyond the final dose.